Amrad halts buyback during Avexa spin-out
Thursday, 01 July, 2004
Amrad (ASX:AML) has halted its share buy-back program while it readies itself to spin out its anti-infectives program.
The process will allow the company to calculate the entitlements of shareholders so that shares can be distributed into the new company, Avexa, during the demerger. Amrad shareholders will receive shares in Avexa on a pro rata basis according to their holdings in Amrad on the record date for the offer.
The Amrad share buy-back program will continue once the record date has passed, the company said.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
